259 related articles for article (PubMed ID: 18451215)
21. Akt activates the mammalian target of rapamycin by regulating cellular ATP level and AMPK activity.
Hahn-Windgassen A; Nogueira V; Chen CC; Skeen JE; Sonenberg N; Hay N
J Biol Chem; 2005 Sep; 280(37):32081-9. PubMed ID: 16027121
[TBL] [Abstract][Full Text] [Related]
22. Prolactin activates mammalian target-of-rapamycin through phosphatidylinositol 3-kinase and stimulates phosphorylation of p70S6K and 4E-binding protein-1 in lymphoma cells.
Bishop JD; Nien WL; Dauphinee SM; Too CK
J Endocrinol; 2006 Aug; 190(2):307-12. PubMed ID: 16899564
[TBL] [Abstract][Full Text] [Related]
23. Interferon beta augments tuberous sclerosis complex 2 (TSC2)-dependent inhibition of TSC2-null ELT3 and human lymphangioleiomyomatosis-derived cell proliferation.
Goncharova EA; Goncharov DA; Chisolm A; Spaits MS; Lim PN; Cesarone G; Khavin I; Tliba O; Amrani Y; Panettieri RA; Krymskaya VP
Mol Pharmacol; 2008 Mar; 73(3):778-88. PubMed ID: 18094073
[TBL] [Abstract][Full Text] [Related]
24. A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression.
Buller CL; Loberg RD; Fan MH; Zhu Q; Park JL; Vesely E; Inoki K; Guan KL; Brosius FC
Am J Physiol Cell Physiol; 2008 Sep; 295(3):C836-43. PubMed ID: 18650261
[TBL] [Abstract][Full Text] [Related]
25. G1 cell cycle progression and the expression of G1 cyclins are regulated by PI3K/AKT/mTOR/p70S6K1 signaling in human ovarian cancer cells.
Gao N; Flynn DC; Zhang Z; Zhong XS; Walker V; Liu KJ; Shi X; Jiang BH
Am J Physiol Cell Physiol; 2004 Aug; 287(2):C281-91. PubMed ID: 15028555
[TBL] [Abstract][Full Text] [Related]
26. Activation of the phosphoinositide 3-kinase-Akt-mammalian target of rapamycin signaling pathway is required for metabotropic glutamate receptor-dependent long-term depression.
Hou L; Klann E
J Neurosci; 2004 Jul; 24(28):6352-61. PubMed ID: 15254091
[TBL] [Abstract][Full Text] [Related]
27. Direct inhibition of the signaling functions of the mammalian target of rapamycin by the phosphoinositide 3-kinase inhibitors, wortmannin and LY294002.
Brunn GJ; Williams J; Sabers C; Wiederrecht G; Lawrence JC; Abraham RT
EMBO J; 1996 Oct; 15(19):5256-67. PubMed ID: 8895571
[TBL] [Abstract][Full Text] [Related]
28. A genetic mouse model of invasive endometrial cancer driven by concurrent loss of Pten and Lkb1 Is highly responsive to mTOR inhibition.
Cheng H; Liu P; Zhang F; Xu E; Symonds L; Ohlson CE; Bronson RT; Maira SM; Di Tomaso E; Li J; Myers AP; Cantley LC; Mills GB; Zhao JJ
Cancer Res; 2014 Jan; 74(1):15-23. PubMed ID: 24322983
[TBL] [Abstract][Full Text] [Related]
29. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.
Blando J; Portis M; Benavides F; Alexander A; Mills G; Dave B; Conti CJ; Kim J; Walker CL
Am J Pathol; 2009 May; 174(5):1869-79. PubMed ID: 19395652
[TBL] [Abstract][Full Text] [Related]
30. PKB/Akt mediates radiosensitization by the signaling inhibitor LY294002 in human malignant gliomas.
Nakamura JL; Karlsson A; Arvold ND; Gottschalk AR; Pieper RO; Stokoe D; Haas-Kogan DA
J Neurooncol; 2005 Feb; 71(3):215-22. PubMed ID: 15735908
[TBL] [Abstract][Full Text] [Related]
31. Signaling events downstream of mammalian target of rapamycin complex 2 are attenuated in cells and tumors deficient for the tuberous sclerosis complex tumor suppressors.
Huang J; Wu S; Wu CL; Manning BD
Cancer Res; 2009 Aug; 69(15):6107-14. PubMed ID: 19602587
[TBL] [Abstract][Full Text] [Related]
32. Important role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice.
Huang X; Wullschleger S; Shpiro N; McGuire VA; Sakamoto K; Woods YL; McBurnie W; Fleming S; Alessi DR
Biochem J; 2008 Jun; 412(2):211-21. PubMed ID: 18387000
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of Growth of TSC2-Null Cells by a PI3K/mTOR Inhibitor but Not by a Selective MNK1/2 Inhibitor.
Evans JF; Rue RW; Mukhitov AR; Obraztsova K; Smith CJ; Krymskaya VP
Biomolecules; 2019 Dec; 10(1):. PubMed ID: 31878201
[TBL] [Abstract][Full Text] [Related]
34. Tuberous-sclerosis complex-related cell signaling in the pathogenesis of lung cancer.
Fuchs A; König K; Heukamp LC; Fassunke J; Kirfel J; Huss S; Becker AJ; Büttner R; Majores M
Diagn Pathol; 2014 Mar; 9():48. PubMed ID: 24593867
[TBL] [Abstract][Full Text] [Related]
35. Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway.
Pore N; Jiang Z; Shu HK; Bernhard E; Kao GD; Maity A
Mol Cancer Res; 2006 Jul; 4(7):471-9. PubMed ID: 16849522
[TBL] [Abstract][Full Text] [Related]
36. Type 1 insulin-like growth factor regulates MT1-MMP synthesis and tumor invasion via PI 3-kinase/Akt signaling.
Zhang D; Brodt P
Oncogene; 2003 Feb; 22(7):974-82. PubMed ID: 12592384
[TBL] [Abstract][Full Text] [Related]
37. Mammalian target of rapamycin positively regulates collagen type I production via a phosphatidylinositol 3-kinase-independent pathway.
Shegogue D; Trojanowska M
J Biol Chem; 2004 May; 279(22):23166-75. PubMed ID: 15047702
[TBL] [Abstract][Full Text] [Related]
38. PTEN deficiency is associated with reduced sensitivity to mTOR inhibitor in human bladder cancer through the unhampered feedback loop driving PI3K/Akt activation.
Seront E; Pinto A; Bouzin C; Bertrand L; Machiels JP; Feron O
Br J Cancer; 2013 Sep; 109(6):1586-92. PubMed ID: 23989949
[TBL] [Abstract][Full Text] [Related]
39. Mutations in the PI3K/PTEN/TSC2 pathway contribute to mammalian target of rapamycin activity and increased translation under hypoxic conditions.
Kaper F; Dornhoefer N; Giaccia AJ
Cancer Res; 2006 Feb; 66(3):1561-9. PubMed ID: 16452213
[TBL] [Abstract][Full Text] [Related]
40. Stimulation of signal transducer and activator of transcription-1 (STAT1)-dependent gene transcription by lipopolysaccharide and interferon-gamma is regulated by mammalian target of rapamycin.
Kristof AS; Marks-Konczalik J; Billings E; Moss J
J Biol Chem; 2003 Sep; 278(36):33637-44. PubMed ID: 12807916
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
